Teleflex Incorporated expanded its Board of Directors from eight to nine members and elected Sean M. Salmon as a new director effective September 8, 2026. Mr. Salmon, age 61, brings over three decades of experience in the medical technology sector, including more than twenty years at Medtronic plc where he served as Executive Vice President and President of the Cardiovascular Portfolio. He will also serve on the company's Growth and Operating Committee. This appointment contributes to significant board refreshment, with one-third of the Board refreshed in 2026. Teleflex operates in the medical technology industry, providing a diverse portfolio of solutions including anesthesia, surgical, vascular access, and urology products.

Teleflex entered into an accelerated share repurchase agreement with Truist Bank to buy back $250 million of common stock on August 7, 2026. The transaction is funded by proceeds from the sale of its Original Equipment Manufacturing and Development Services business and executed under a previously announced $1 billion program. Initial delivery of shares representing 80% of the repurchase price will occur on August 10, 2026, with final settlement expected in the fourth quarter of 2026 based on volume-weighted average prices. Teleflex operates in the medical technology industry, manufacturing and distributing medical devices and equipment.

Teleflex reported second quarter 2026 financial results, posting revenue from continuing operations of $570.3 million, up 28.9% year-over-year, and adjusted diluted EPS of $1.76. The company completed the divestiture of its OEM business for approximately $1.5 billion in cash, with estimated after-tax proceeds of $1.25 billion, which were used to pay off a $700 million Term Loan A-2. Teleflex repurchased 1.9 million shares for $250 million during the quarter and announced a new $250 million accelerated share repurchase program effective August 7, 2026. Management reduced full-year 2026 GAAP revenue growth guidance to 13.4%–14.4% and adjusted diluted EPS guidance to $6.90–$7.20, citing slower-than-expected integration of the acquired Vascular Intervention business from BIOTRONIK. The company also received FDA approval for EZPLAZ freeze-dried plasma and advanced clinical trials for its Freesolve magnesium scaffold. Teleflex is a global provider of medical technologies and devices.

Teleflex Incorporated filed an amendment to its August 3, 2026 Form 8-K to include unaudited pro forma financial information required under Item 9.01(b) following the completion of the sale of its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc. The transaction closed on August 3, 2026, generating net cash proceeds of $1.5 billion, or approximately $1.24 billion after-tax, which were used to repay $700 million in debt. The pro forma financials reflect the elimination of the OEM business's assets and liabilities as of March 31, 2026, and its historical results for the year ended December 31, 2025, along with adjustments for ancillary transition agreements. Teleflex is a global provider of medical technology products focused on enhancing clinical benefits and patient safety through single-use medical devices.

Teleflex completed the sale of its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc. on August 3, 2026, for a purchase price of $1.5 billion in cash. The transaction includes ancillary agreements such as transition services, development, and long-term supply arrangements. Teleflex estimates after-tax proceeds of approximately $1.25 billion, which it intends to use for debt reduction and share repurchases. This divestiture is part of the company's transformation strategy to sharpen its focus on continuing businesses. Teleflex operates in the medical technology industry, providing solutions in anesthesia, emergency medicine, interventional cardiology, surgical, vascular access, and urology.

Teleflex Incorporated issued $500,000,000 in 5.875% senior notes due January 2032, which pay interest semi-annually on January 15 and July 15. The notes are general unsecured senior obligations of the company and its domestic subsidiaries. Teleflex Incorporated is a medical technology company that develops and manufactures products for various medical specialties.